SSSotir Stavridis

Sotir Stavridis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sotir Stavridis has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksandar Josifov

    University Clinic for Thoracic and Vascular surgery, Medical Faculty, Ss Cyril and Methodius University in Skopje, Skopje, RN Macedonia

    1 shared publication
  • Aleksandra Gavrilovska-Brzanov

    Department of Anesthesiology, Reanimation and Intensive Care Medicine and Emergency, Ss. Cyril and Methodius University in Skopje Faculty of Medicine, Skopje, Republic of North Macedonia

    1 shared publication
  • Asim Musa

    University Clinic for Urology, Medical Faculty, Ss Cyril and Methodius University in Skopje, Skopje, RN Macedonia

    1 shared publication
  • Baskim Shabani

    University Clinic for Urology, Medical Faculty, Ss Cyril and Methodius University in Skopje, Skopje, RN Macedonia

    1 shared publication
  • Dimitar Temelkovski

    General Hospital "Borka Taleski", Prilep, RN Macedonia

    1 shared publication
  • Dimitar Trajkovski

    Department of Urology, Ss. Cyril and Methodius University in Skopje Faculty of Medicine, Skopje, Republic of North Macedonia

    1 shared publication

Latest Publications

  • Open Access

    Renal Function Improvement after Transurethral Prostate Vaporesection with Thulium YAG Laser and Resection with High- Frequency Electrical Current

    by Dimitar Trajkovski, Dimitar Temelkovski, Sotir Stavridis, Josif Janculev, Ognen Ivanovski, Baskim Shabani, Asim Musa, Viktor Stankov, Ivo Vuicic, Kosta Dohchev, et al.

    Introduction. Benign prostatic hyperplasia/Benign prostatic obstruction (BPH/BPO) and chronic kidney disease (CKD) are two important public health problems in elderly men, with a huge medical and social impact on rapidly aging population globally. Clinical studies have proven obstruction of the lower urinary tract, secondary to BPO as a cause of a decreased renal fun- ction and CKD development. Conversely, the reverse process of the lower urinary tract obstruction relieve should be improving the renal function. The aim of this study is to evaluate the possibility of simultaneous improvement in renal function with transurethral prostate surgery for treatment of BPO. Methods. A randomized, study (1:1) initiated in July 2022 at the University clinic for urology in Skopje, Republic of N Macedonia, was conducted on 40 patients with BPO to compare the efficacy and safety of the two endourological transurethral surgical methods for BPO treatment: in our country the recently introduced Tm:YAG laser transurethral vaporesection of the prostate (ThuVARP) and the traditional and well-established method of transurethral resection of the prostate (TURP) by using high-frequency electric current (TURP). For evaluation two types of indicators were used, BPO related and renal function (RF) related indicators. The BPO related indicators (International Prostate Symptom Score-IPSS, maximum flow rate- Qmax, prostate volume-V, and post-void residual urine volume-PVR) were assessed preoperatively and reassessed at 6 months postoperatively. RF related indicators (serum potassium, serum creatinine, and estimated glomerular filtration rate (eGFR) evaluated with the 2021 Creatinine equation (CKD-EPI) were also assessed preoperatively and reassessed after 7-10 days, postoperatively. By comparing the pre and postoperative values within each surgical group, conclusions were drawn about the possible effect of BPO surgery on renal function improvement. Other risk factors for CKD like diabetes, hypertension, smoking, obesity, dyslipidemia and metabolic syndrome were not considered in this study. Results. Significant improvements were observed postoperatively in all BPO related indicators in both surgical groups. In the ThuVARP group, Qmax increased from 6.06 ± 2.1 to 16.59 ± 6.2 ml/s (p=0.00) and IPSS, prostate V and PVR decreased from 25 ± 1.9 to 3.56 ± 5 (p=0.00); 61.4 ± 33.4 to 26.2 ± 11.9 ml (p=00); and 142.8 ± 79.1 to 7.97 ± 11ml (p=0.00); and ml (p=0.00), respectively. In the TURP group, Qmax increased from 7.96 ± 3.5 to 18.14 ± 6.6 ml/s (p=0.00); and IPSS, prostate V and PVR decreased from 22.89 ± 4.4 to 6.68 ± 5 (p=0.00); 61.5 ± 16.2 to 21.13 ± 14.4 ml (p=0.00); and 128.9 ± 86.1 to 23.45 ± 47.2 ml (p=0.00), respectively. RF related indicators also presented significant improvements postoperatively. In the ThuVARP group, serum potassium and serum creatinine decreased from 4.44 ± 0.5 to 4.17 ± 0.4 mmol/l (p=0.019) and 86.77 ± 23.2 to 78.84 ± 19.3 (p=0.029), respectively and eGFR increased from 83.26 ± 18.3 to 88.63 ± 88.63 ± 15 ml/min/1.73m2 (p=0.049). In the TURP group, serum potassium and serum creatinine decreased from 4.32 ± 0.3 to 4.13 ± 0.5 mmol/L (p=0041); and 78.59 ± 12.3 to 73.44 ± 12 nmol/L (p=0.004), respectively and eGFR, increased from 89.05 ± 11.8 to 93.65 ± 10.70 ml/min/1.73m2 (p=0.0028). Conclusion. Our findings suggest that prostate surgery with consecutive relief of the lower urinary tract obstruction, regardless of the chosen method (ThuVARP or TURP) may improve the renal function and be potentially benefitial in CKD patients.

  • Open Access

    AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study

    by Selim Komina, Gordana Petrusevska, Rubens Jovanovic, Slavica Kostadinova Kunovska, Sotir Stavridis, Saso Dohcev, Skender Saidi, Sonja Topuzovska

    Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n=37), with histologically proven bladder cancer, and control group (n=30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surger y and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t-test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation=10.04, range=43-82 years) and the control group was 59.67 years (standard deviation=10.44, range=38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n=19; 28.4%), Primary tumor (pT) in situ (n=4; 6%), pT1 (n=7; 10.4%), and pT≥2 (n=7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation=114.91) compared to controls 5.28 pg/mL (standard deviation=6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n=23; mean=7.14 pg/mL; standard deviation=7.26) and invasive bladder cancer (n=14; mean=117.99 pg/mL; standard deviation=168.08) and between non-muscle invasive bladder cancer (mean=23.19 pg/mL; standard deviation=66.93) and muscle-invasive bladder cancer (mean=160.05 pg/mL; standard deviation=199.65) (P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies. Cite this article as: Komina S, Petrusevska G, Jovanovic R, et al. AHNAK2 urinary protein expression as potential biomarker for bladder cancer detection: A pilot study. Turk J Urol. 2022;48(6):423-430.